Alnylam reports positive interim results from ongoing phase 1 study of aln-agt, an investigational rnai therapeutic for the treatment of hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today positive interim data from the ongoing phase 1 study of aln-agt, a subcutaneous investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) for the treatment of hypertension. results were presented in a poster presentation at the american heart association (aha) scientific sessions 2020, taking place virtually from november 13 – 17, 2020. d
ALNY Ratings Summary
ALNY Quant Ranking